美国儿童和青少年急性肺栓塞(2016年和2019年):一项全国性回顾性队列研究
该研究基于美国儿童住院患者数据库,纳入2016年和2019年因急性肺栓塞住院的0-19岁患者5733例(女性58.5%,男性41.5%),估计年发病率为3.5/10万人(95%CI 3.4-3.6),发病率在<1岁婴儿和15-19岁青少年出现两个高峰。院内病死率为4.5%(95%CI 4.0-5.1),急性肺栓塞患者院内死亡的粗比值比为9.3(95%CI 7.9-10.9),且在多变量模型中关联持续存在。高危特征患者死亡风险最高:0-9岁为25.3%(95%CI 20.6-30.5),10-19岁为13.9%(95%CI 11.9-16.2);无高危特征者病死率分别为4.9%(95%CI 3.1-7.6)和0.7%(95%CI 0.5-1.0)。颅内出血风险同样在高危特征患者中最高:0-9岁为8.1%(95%CI 5.5-11.7),10-19岁为3.6%(95%CI 2.6-4.9);无高危特征者分别为2.5%(95%CI 1.3-4.6)和0.5%(95%CI 0.3-0.8)。除全身溶栓外,再灌注治疗在儿童青少年急性肺栓塞中很少使用。
要点
- 美国0-19岁儿童青少年急性肺栓塞年发病率为3.5/10万人(95%CI 3.4-3.6),婴儿<1岁和青少年15-19岁为两个发病高峰。
- 急性肺栓塞患者院内病死率4.5%(95%CI 4.0-5.1),合并急性肺栓塞者院内死亡粗比值比为9.3(95%CI 7.9-10.9)。
- 高危特征患者死亡风险最高:0-9岁25.3%(95%CI 20.6-30.5),10-19岁13.9%(95%CI 11.9-16.2);无高危特征者分别为4.9%(95%CI 3.1-7.6)和0.7%(95%CI 0.5-1.0)。
- 颅内出血风险在高危特征患者中最高:0-9岁8.1%(95%CI 5.5-11.7),10-19岁3.6%(95%CI 2.6-4.9);无高危特征者分别为2.5%(95%CI 1.3-4.6)和0.5%(95%CI 0.3-0.8)。
- 除全身溶栓外,再灌注治疗在儿童青少年急性肺栓塞中很少使用。
适用人群与场景
- 美国0-19岁儿童和青少年,因急性肺栓塞作为主要诊断或伴随诊断住院的患者,数据来自2016年和2019年儿童住院患者数据库。
- 同时使用美国多死因数据库和美国人口普查局人口数据估计发病率、死亡率、病死率和比例死亡率。
研究设计与关键结果
- 研究类型:全国性回顾性队列研究,基于儿童住院患者数据库,纳入2016年和2019年美国0-19岁急性肺栓塞住院患者5733例(女性3353例[58.5%],男性2380例[41.5%])。
- 年发病率为3.5/10万人(95%CI 3.4-3.6),发病率在<1岁婴儿和15-19岁青少年出现两个高峰。
- 院内病死率为4.5%(95%CI 4.0-5.1);急性肺栓塞患者(对比无急性肺栓塞者)院内死亡的粗比值比为9.3(95%CI 7.9-10.9),该关联在不同多变量模型中持续存在。
- 高危特征患者(对比无高危特征者)死亡风险最高:0-9岁为25.3%(95%CI 20.6-30.5),10-19岁为13.9%(95%CI 11.9-16.2);无高危特征者病死率分别为4.9%(95%CI 3.1-7.6)和0.7%(95%CI 0.5-1.0)。
- 颅内出血风险在高危特征患者中最高:0-9岁为8.1%(95%CI 5.5-11.7),10-19岁为3.6%(95%CI 2.6-4.9);无高危特征者分别为2.5%(95%CI 1.3-4.6)和0.5%(95%CI 0.3-0.8)。
- 除全身溶栓外,再灌注治疗在儿童青少年急性肺栓塞中很少使用。
证据类型、等级与局限
- 证据类型:全国性回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:儿童和青少年急性肺栓塞罕见;特定亚组中肺栓塞相关的高病死率可结合严重合并症和高危特征肺栓塞事件来解读。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Epidemiological data on acute pulmonary embolism among children and adolescents are sparse and only date back to the 2000s. We aimed to establish annual estimates and age-stratified and sex-stratified indicators of acute pulmonary embolism among children and adolescents aged 0-19 years.
METHODS: We did a retrospective, nationwide, patient-level analysis of the Kids' Inpatient Database, including 5733 patients with acute pulmonary embolism aged 0-19 years admitted to hospital in the USA in 2016 and 2019. The database includes data of all children admitted to hospital during the 2 years available. We also accessed the US Multiple Cause of Death database and population data from the US Census Bureau for the same 2 years. We estimated the incidence, mortality, case fatality, and proportional mortality rates, provided data on the annual pulmonary embolism burden, and provided data on clinical events recorded during hospitalisation.
FINDINGS: In the years 2016 and 2019, 5733 patients (3353 [58.5%] female and 2380 [41.5%] male) were admitted to hospital with acute pulmonary embolism as the primary diagnosis or a concomitant diagnosis. The annual incidence of acute pulmonary embolism was 3·5 (95% CI 3·4-3·6) per 100 000 people. Two peaks in the incidence rate were observed-one in infants younger than 1 year and one in adolescents aged 15-19 years. The in-hospital case fatality rate was 4·5% (4·0-5·1). The crude odds ratio for in-hospital death among patients with (vs without) acute pulmonary embolism was 9·3 (7·9-10·9). The association between acute pulmonary embolism and death persisted across different multivariable models. Patients with acute pulmonary embolism with high-risk (vs no high-risk) features had the highest risk of death: 25·3% (20·6-30·5) among patients aged 0-9 years and 13·9% (11·9-16·2) among patients aged 10-19 years. In patients without high-risk features, risk of death was 4·9% (3·1-7·6) among patients aged 0-9 years and 0·7% (0·5-1·0) among patients aged 10-19 years. The risk of intracranial bleeding was also highest in the presence of pulmonary embolism with high-risk features: 8·1% (5·5-11·7) among patients aged 0-9 years and 3·6% (2·6-4·9) among patients aged 10-19 years. In patients without high-risk features, the risk of intracranial bleeding was 2·5% (1·3-4·6) among those aged 0-9 years and 0·5% (0·3-0·8) in those aged 10-19 years. Reperfusion treatments beyond systemic thrombolysis were rarely used among children and adolescents with acute pulmonary embolism.
INTERPRETATION: Acute pulmonary embolism is rare during childhood and adolescence. The high pulmonary embolism-related fatality among specific subgroups of patients can be interpreted in the context of severe comorbidities and pulmonary embolism events with high-risk features.
参考来源
- Wolf S, Valerio L, Kucher N, et al. Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort study. Lancet Respir Med. 2025. PMID: 39919780. doi:10.1016/S2213-2600(24)00412-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。